BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 15701145)

  • 1. Fondaparinux: an update on new study results.
    Bauersachs RM
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
    Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
    Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
    Eriksson BI; Lassen MR;
    Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
    Bauer KA
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pentasaccharides. The new anticoagulants.
    Abdel-Razeq H
    Saudi Med J; 2004 Aug; 25(8):983-90. PubMed ID: 15322584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism in the medically ill patient: a call to action.
    Bergmann JF; Kher A
    Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
    Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
    J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux for post-operative venous thrombosis prophylaxis.
    Garces K
    Issues Emerg Health Technol; 2002 Aug; (37):1-4. PubMed ID: 12195605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.